TGFB1 and silicosis: Stem cell-based therapies have emerged as a promising therapeutic modality for silicosis, leveraging their inherent biological properties to target key pathogenic cascades, such as NLRP3 inflammasome activation, TGF-β1/Smad-mediated fibrotic progression, and Th1/Th2 immune homeostasis imbalance.